Healthcare Industry News: sanofi-aventis
News Release - October 31, 2007
Dyax Announces the Appointment of William Pullman as Executive Vice President and Chief Development OfficerCAMBRIDGE, Mass.--(HSMN NewsFeed)--Dyax Corp. (NASDAQ: DYAX ) today announced that William Pullman, M.D., Ph.D. has joined the Company as Executive Vice President and Chief Development Officer. In this position, Dr. Pullman will oversee Clinical, Regulatory and Program Management departments at Dyax.
Dr. Pullman brings over 25 years of medical experience to Dyax, with the early focus of his career in research. Most recently, he served as Senior Vice President and Chief Medical Officer at Cubist Pharmaceuticals, where he integrated the existing Clinical Development and Medical Affairs departments as well as drove value creation for its product. Prior to Cubist, Dr. Pullman served as Senior Vice President, Exploratory Development at Transform Pharmaceuticals, where he was tasked with building and leading the clinical team to support product development efforts. Additionally, he also held numerous clinical positions at sanofi-aventis, Eli Lilly and Company and Pfizer.
“I’m pleased to have Dr. Pullman join the Dyax executive management team,” commented Henry Blair, Chairman, President and Chief Executive Officer of Dyax. “Dr. Pullman brings to the Company a depth of experience and expertise in clinical trials and product development. He will be a tremendous asset to us.” Mr. Blair commented further, “With anticipation of approval of DX-88 for hereditary angioedema by the end of 2008, I look forward to working with him on other indications currently in the clinic, expanding the DX-88 franchise and also on our extensive drug discovery pipeline.”
Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development.
Dyax’s lead product candidate is DX-88, a recombinant small protein that is currently in clinical trials for its therapeutic potential in two separate indications. Dyax has completed three Phase 2 trials and a Phase 3 trial of DX-88 for the treatment of hereditary angioedema (HAE). A second Phase 3 trial, known as EDEMA4, is currently being conducted under a Special Protocol Assessment (SPA). DX-88 has orphan drug designation in the U.S. and E.U., as well as Fast Track designation in the U.S. for the treatment of acute attacks of HAE.
Additionally, Dyax has completed a Phase 1/2 trial of DX-88 for the prevention of blood loss during on-pump coronary artery bypass graft (CABG) procedures. A Phase 2 trial for further development of DX-88 in on-pump cardiothoracic surgery (CTS), including CABG and heart valve replacement or repair procedures, is ongoing.
Dyax identified DX-88 and other compounds in its pipeline using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents.
Dyax is headquartered in Cambridge, Massachusetts, and has antibody discovery facilities in Liege, Belgium. For online information about Dyax Corp., please visit www.dyax.com.
This press release contains forward-looking statements, including statements regarding the progress of ongoing clinical trials and the prospects for regulatory filings and approvals for DX-88. Statements that are not historical facts are based on Dyax’s current expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in which Dyax competes. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect the prospects for regulatory filings for DX-88 include the risks that: DX-88 may not show therapeutic effect or an acceptable safety profile in clinical trials or could take a significantly longer time to gain regulatory approval than Dyax expects or may never gain approval; others may develop technologies or products superior to DX-88; Dyax is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacture, marketing, sales and distribution of its biopharmaceuticals; DX-88 may not gain market acceptance; Dyax may not be able to obtain and maintain intellectual property protection for DX-88 for the duration of its patent covering DX-88; and other risk factors described or referred to in Dyax’s most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Dyax undertakes no obligations to update or revise these statements, except as may be required by law.
Dyax and the Dyax logo are registered trademarks of Dyax Corp. EDEMA4 is a service mark of Dyax Corp.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.